Targeting IL-22 in AD: A Q&A About LEO Pharma’s Temtokibart With Michael Ardern-Jones
The investigational atopic dermatitis (AD) agent temtokibart (LEO Pharma) hit its primary efficacy endpoint for three of the highest doses in Phase 2b data recently presented at the 2025 European Academy of Dermatology and Venereology (EADV) Conference in Paris, France.